Advertisement

Topics

Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma

2018-09-05 00:28:12 | BioPortfolio

Published on BioPortfolio: 2018-09-05T00:28:12-0400

Clinical Trials [1664 Associated Clinical Trials listed on BioPortfolio]

Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies

In severe prednisone-dependent eosinophilic asthma, Benralizumab would suppress airway eosinophilia that is not suppressed by either Mepolizumab or Reslizumab and this would be associated ...

Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.

This study will generate patient reported outcomes (PROs) associated with the use of benralizumab as treatment for severe eosinophilic asthma.

Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI

The purpose of this study is to evaluate the effect of a drug called benralizumab in individuals with severe, poorly controlled asthma with eosinophilic airway inflammation. Eosinophils ar...

The Effect of Benralizumab on Exercise-induced Bronchoconstriction

Severe asthma affects 5-10% of more than 300 million asthmatics. Ten to twenty percent of individuals suffering from asthma do not respond well to current treatment due to the complexity o...

Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis

The objective of this study is to evaluate the efficacy and safety of SC administrations of Benralizumab or Placebo in the subjects with Eosinophilic Chronic Rhinosinusitis in a multicente...

PubMed Articles [5444 Associated PubMed Articles listed on BioPortfolio]

Relationship Between Benralizumab Exposure and Efficacy for Patients with Severe Eosinophilic Asthma.

We evaluated the relationship between benralizumab (30 mg every 4 and 8 weeks [Q4W, Q8W]) pharmacokinetic (PK) exposure and endpoints of asthma exacerbation rates (AER) and change from baseline in pre...

Favorable response to asthma-dosed subcutaneous mepolizumab in eosinophilic pneumonia.

Mepolizumab targets eosinophils in the treatment of asthma. The dose used for asthma is considerably lower than that used for treating eosinophilic granulomatosis with polyangiitis, a recently approve...

The prevalence and disease burden of severe eosinophilic asthma in Japan.

There are limited data on the prevalence and burden of severe eosinophilic asthma (SEA) both in Japan and globally. This study aimed to assess the prevalence and burden of SEA in Japan.

Anti-IL5 in Mild Asthma Alters Rhinovirus-Induced Macrophage, B Cell and Neutrophil Responses (MATERIAL): A Placebo-Controlled, Double-Blind Study.

Eosinophils drive pathophysiology in stable and exacerbating eosinophilic asthma and therefore treatment is focused on the reduction of eosinophil numbers. Mepolizumab, a humanized monoclonal antibody...

Dupixent, a New Entrant In the Asthma Lists.

Sanofi and Regeneron's Dupixent (dupilumab)-which is already approved for atopic dermatitis-has an FDA action date of October 20 for its asthma indication. It will join Nucala, (mepolizumab), Cinqair ...

Medical and Biotech [MESH] Definitions

A condition characterized by infiltration of the lung with EOSINOPHILS due to inflammation or other disease processes. Major eosinophilic lung diseases are the eosinophilic pneumonias caused by infections, allergens, or toxic agents.

Asthma attacks caused, triggered, or exacerbated by OCCUPATIONAL EXPOSURE.

Thermal destruction of the excess bronchial SMOOTH MUSCLE tissue with heat delivered through a catheter assembly attached to a BRONCHOSCOPE. It is often used to control BRONCHIAL HYPERREACTIVITY in severe ASTHMA for better AIRWAY MANAGEMENT.

A clear, homogenous, structureless, eosinophilic substance occurring in pathological degeneration of tissues.

Asthma attacks following a period of exercise. Usually the induced attack is short-lived and regresses spontaneously. The magnitude of postexertional airway obstruction is strongly influenced by the environment in which exercise is performed (i.e. inhalation of cold air during physical exertion markedly augments the severity of the airway obstruction; conversely, warm humid air blunts or abolishes it).

More From BioPortfolio on "Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial